We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Targeting the CCND1-PDK4 Axis to Promote Reparative Macrophage Phenotype and Mitigate Post-Myocardial Infarction Cardiac Remodeling

MedXY Editorial Team•Sep 19, 2026•Cardiology
Metabolic Reprogrammingマクロファージ極性化CCND1Cardiac Remodelingmyocardial infarction

Highlight

  • CCND1 expression decreases in monocytes and cardiac macrophages after myocardial infarction (MI), correlating with adverse cardiac remodeling.
  • Macrophage-specific deletion of CCND1 exacerbates inflammation and worsens cardiac dysfunction following MI.
  • CCND1 interacts with PDK4, facilitating its ubiquitination via RPL11 and MDM2, suppressing PDK4’s phosphorylation of PDH, thereby enhancing glucose oxidation in macrophages.
  • Therapeutic targeting of the CCND1-PDK4 axis in macrophages promotes reparative phenotype transition, improving cardiac function post-MI independently of CCND1’s cell cycle role.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic TherapyThis study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.Sep 19, 2026Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D TrialThe TARGET-D trial investigated whether vitamin D supplementation, titrated to achieve serum levels >40-80 ng/mL, reduces major adverse cardiovascular events after myocardial infarction but found no significant benefit in the primary comSep 17, 2026Comparing 0/1-Hour vs 0/3-Hour High-Sensitivity Troponin Pathways for Suspected Acute Coronary Syndrome in Real-World PracticeThis randomized trial evaluates the safety and efficiency of the ESC 0/1-hour versus 0/3-hour high-sensitivity troponin pathways in suspected acute coronary syndrome, showing noninferior safety but no significant improvement in rapid dischaSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Illuminating the Night: How Nighttime Light Exposure Impacts Cardiac Structure, Function, and Cardiovascular Risk
Nighttime light exposure over 3 lux is linked to adverse cardiac remodeling, subclinical functional decline, and increased cardiovascular events, partly mediated by shorter sleep duration, underscoring the importance of dark nights and slee
Sep 15, 2026
Stent Retriever Thrombectomy Reduces Infarct Size in High-Thrombus Myocardial Infarction: Insights from the NATURE TrialThe NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.Sep 6, 2026
Oral Relaxin Receptor Agonist AZD5462 Shows Promise in Chronic Heart Failure: Insights from the LUMINARA TrialThe LUMINARA trial evaluates AZD5462, an oral relaxin receptor agonist, demonstrating safety and promising effects on cardiac remodeling and vascular resistance in chronic heart failure, warranting further large-scale investigation.Sep 3, 2026